• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Earnings Scheduled For March 31, 2023

    3/31/23 11:45:09 AM ET
    $ADN
    $ALAR
    $ALIM
    $AUVI
    Industrial Machinery/Components
    Miscellaneous
    Computer Software: Prepackaged Software
    Technology
    Get the next $ADN alert in real time by email

    Companies Reporting Before The Bell

    • Pioneer Muni High Inc (NYSE:MAV) is likely to report quarterly earnings at $0.05 per share on revenue of $35.00 million.

    • Bio-Path Holdings (NASDAQ:BPTH) is likely to report earnings for its fourth quarter.

    • Crown ElectroKinetics (NASDAQ:CRKN) is estimated to report earnings for its fourth quarter.

    • Carlyle Group (NASDAQ:CG) is likely to report earnings for its first quarter.

    • Chemomab Therapeutics (NASDAQ:CMMB) is expected to report earnings for its fourth quarter.

    • P3 Health Partners (NASDAQ:PIII) is expected to report quarterly loss at $0.91 per share on revenue of $252.95 million.

    • Bioventus (NASDAQ:BVS) is projected to report quarterly earnings at $0.05 per share on revenue of $132.70 million.

    • Creative Media (NASDAQ:CMCT) is likely to report quarterly loss at $0.16 per share on revenue of $25.22 million.

    • PyroGenesis Canada (NASDAQ:PYR) is likely to report earnings for its fourth quarter.

    • Nuvve Holding (NASDAQ:NVVE) is likely to report quarterly loss at $0.32 per share on revenue of $800 thousand.

    • Strata Skin Sciences (NASDAQ:SSKN) is projected to report quarterly loss at $0.05 per share on revenue of $9.82 million.

    • Tivic Health Systems (NASDAQ:TIVC) is estimated to report quarterly loss at $0.31 per share on revenue of $640 thousand.

    • Alarum Technologies (NASDAQ:ALAR) is likely to report quarterly loss at $0.78 per share on revenue of $5.03 million.

    • Alimera Sciences (NASDAQ:ALIM) is projected to report quarterly loss at $0.33 per share on revenue of $14.62 million.

    • Data Storage (NASDAQ:DTST) is expected to report earnings for its fourth quarter.

    • BIO-key Intl (NASDAQ:BKYI) is estimated to report quarterly loss at $0.27 per share on revenue of $1.74 million.

    • Harbor Custom Dev (NASDAQ:HCDI) is likely to report quarterly loss at $3.40 per share on revenue of $12.60 million.

    • Advent Technologies Hldgs (NASDAQ:ADN) is estimated to report earnings for its fourth quarter.

    • I-MAB (NASDAQ:IMAB) is estimated to report earnings for its Fiscal Year 2022.

    • Fathom Digital Mfg (NYSE:FATH) is projected to report quarterly loss at $0.01 per share on revenue of $40.48 million.

    Companies Reporting After The Bell

    • Chicken Soup for the Soul (NASDAQ:CSSE) is expected to report quarterly loss at $1.17 per share on revenue of $112.34 million.

    • Kidpik (NASDAQ:PIK) is estimated to report quarterly loss at $0.32 per share on revenue of $3.70 million.

    • AIM ImmunoTech (AMEX:AIM) is likely to report quarterly loss at $0.12 per share on revenue of $180 thousand.

    • bioAffinity Technologies (NASDAQ:BIAF) is estimated to report earnings for its fourth quarter.

    • Electra Battery Materials (NASDAQ:ELBM) is likely to report earnings for its fourth quarter.

    • Inhibikase Therapeutics (NASDAQ:IKT) is likely to report earnings for its fourth quarter.

    • Applied UV (NASDAQ:AUVI) is estimated to report quarterly loss at $0.18 per share on revenue of $5.50 million.

    • MSP Recovery (NASDAQ:LIFW) is expected to report quarterly earnings at $0.69 per share on revenue of $303.98 million.

    • Williams Ind Servs (AMEX:WLMS) is estimated to report quarterly loss at $0.35 per share on revenue of $54.50 million.

    • Verb Tech (NASDAQ:VERB) is projected to report quarterly loss at $0.05 per share on revenue of $2.61 million.

    • VirTra (NASDAQ:VTSI) is expected to report quarterly loss at $0.01 per share on revenue of $6.64 million.

    • Flexible Solutions Intl (AMEX:FSI) is estimated to report quarterly earnings at $0.10 per share on revenue of $10.41 million.

    • Eastside Distilling (NASDAQ:EAST) is expected to report quarterly loss at $0.17 per share on revenue of $3.66 million.

    • Miromatrix Medical (NASDAQ:MIRO) is expected to report earnings for its fourth quarter.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADN
    $ALAR
    $ALIM
    $AUVI

    CompanyDatePrice TargetRatingAnalyst
    Bioventus Inc.
    $BVS
    2/9/2026$13.00Outperform
    Barrington Research
    Inhibikase Therapeutics Inc.
    $IKT
    1/21/2026$6.00Buy
    BofA Securities
    Inhibikase Therapeutics Inc.
    $IKT
    12/26/2025$8.00Buy
    H.C. Wainwright
    The Carlyle Group Inc.
    $CG
    12/11/2025$74.00Buy
    UBS
    Inhibikase Therapeutics Inc.
    $IKT
    12/11/2025$4.00Overweight
    Cantor Fitzgerald
    I-MAB
    $IMAB
    10/3/2025$9.00Outperform
    Leerink Partners
    The Carlyle Group Inc.
    $CG
    10/3/2025$74.00Outperform
    BMO Capital Markets
    I-MAB
    $IMAB
    9/9/2025$7.00Buy
    BTIG Research
    More analyst ratings

    $ADN
    $ALAR
    $ALIM
    $AUVI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barrington Research initiated coverage on Bioventus with a new price target

    Barrington Research initiated coverage of Bioventus with a rating of Outperform and set a new price target of $13.00

    2/9/26 8:08:39 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    BofA Securities initiated coverage on Inhibikase Therapeutics with a new price target

    BofA Securities initiated coverage of Inhibikase Therapeutics with a rating of Buy and set a new price target of $6.00

    1/21/26 8:55:17 AM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Inhibikase Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Inhibikase Therapeutics with a rating of Buy and set a new price target of $8.00

    12/26/25 8:50:26 AM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADN
    $ALAR
    $ALIM
    $AUVI
    SEC Filings

    View All

    SEC Form EFFECT filed by AIM ImmunoTech Inc.

    EFFECT - AIM ImmunoTech Inc. (0000946644) (Filer)

    2/11/26 12:15:22 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    bioAffinity Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

    2/10/26 5:14:35 PM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form S-1/A filed by AIM ImmunoTech Inc.

    S-1/A - AIM ImmunoTech Inc. (0000946644) (Filer)

    2/10/26 4:35:37 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADN
    $ALAR
    $ALIM
    $AUVI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Sands Capital Life Sciences Pulse Fund Ii, L.P. bought $2,999,999 worth of shares (2,068,965 units at $1.45) (SEC Form 4)

    4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)

    11/24/25 3:47:02 PM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Givens John F. Ii bought $108 worth of shares (22 units at $4.92), increasing direct ownership by 0.01% to 328,388 units (SEC Form 4)

    4 - VirTra, Inc (0001085243) (Issuer)

    11/19/25 4:05:35 PM ET
    $VTSI
    Miscellaneous manufacturing industries
    Consumer Discretionary

    Chief Executive Officer Givens John F. Ii bought $23,743 worth of shares (4,978 units at $4.77), increasing direct ownership by 2% to 328,366 units (SEC Form 4)

    4 - VirTra, Inc (0001085243) (Issuer)

    11/18/25 6:18:17 PM ET
    $VTSI
    Miscellaneous manufacturing industries
    Consumer Discretionary

    $ADN
    $ALAR
    $ALIM
    $AUVI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Polymetallic Explorers Gain Ground as Copper Deficit Reshapes Discovery Premiums

    Issued on behalf of GoldHaven Resource Corp. VANCOUVER, BC, Feb. 11, 2026 /PRNewswire/ -- Equity Insider News Commentary — The International Copper Study Group now projects a 150,000-tonne refined copper deficit for 2026, reversing its earlier surplus forecast as production growth slows to just 0.9% against demand that continues to outpace new supply[1]. Federal investment is widening beyond rare earths to cover high-risk minerals including tungsten and antimony, with MINING.COM reporting that Washington's 2026 policy agenda will prioritize processing capacity for metals where the U.S. remains almost entirely dependent on foreign supply[2]. GoldHaven Resources (CSE:GOH), Emerita Resources (

    2/11/26 9:42:00 AM ET
    $ELBM
    $SVM
    Industrial Machinery/Components
    Miscellaneous
    Precious Metals
    Basic Materials

    AIM ImmunoTech Announces Commencement of Rights Offering

    OCALA, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) – AIM ImmunoTech Inc. ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced that it has commenced its previously disclosed rights offering (the "Rights Offering").  Pursuant to the Rights Offering, the Company is distributing to all holders of record of the Company's common stock, par value $0.001 per share ("Common Stock"), and to holders of certain options and warrants that have the right to participate in the Rights O

    2/11/26 8:30:00 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board

    Advisory Board provides independent guidance on strategic priorities, including growing adoption of the Company's noninvasive CyPath® Lung diagnostic test bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced new appointments to its Medical and Scientific Advisory Board, welcoming David Ost, MD, MPH, University of Texas MD Anderson Cancer Center, Daniel Sterman, MD, New York University Langone Medical Center, and J. Scott Ferguson, MD, University of Wisconsin School of Medicine and Public Health, to its panel of recognized leaders in the field. The appointments reflect a planned expans

    2/9/26 8:00:00 AM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ADN
    $ALAR
    $ALIM
    $AUVI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Executive Officer O Brien Daniel B sold $95,353 worth of shares (16,497 units at $5.78), decreasing direct ownership by 0.36% to 4,595,156 units (SEC Form 4)

    4/A - FLEXIBLE SOLUTIONS INTERNATIONAL INC (0001069394) (Issuer)

    2/10/26 3:14:36 PM ET
    $FSI
    Major Chemicals
    Industrials

    Chief Financial Officer Plouffe Justin covered exercise/tax liability with 46,176 shares, decreasing direct ownership by 5% to 903,717 units (SEC Form 4)

    4 - Carlyle Group Inc. (0001527166) (Issuer)

    2/6/26 5:19:48 PM ET
    $CG
    Investment Managers
    Finance

    General Counsel Ferguson Jeffrey W. covered exercise/tax liability with 937 shares, decreasing direct ownership by 0.12% to 781,130 units (SEC Form 4)

    4 - Carlyle Group Inc. (0001527166) (Issuer)

    2/6/26 5:19:43 PM ET
    $CG
    Investment Managers
    Finance

    $ADN
    $ALAR
    $ALIM
    $AUVI
    Leadership Updates

    Live Leadership Updates

    View All

    bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board

    Advisory Board provides independent guidance on strategic priorities, including growing adoption of the Company's noninvasive CyPath® Lung diagnostic test bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced new appointments to its Medical and Scientific Advisory Board, welcoming David Ost, MD, MPH, University of Texas MD Anderson Cancer Center, Daniel Sterman, MD, New York University Langone Medical Center, and J. Scott Ferguson, MD, University of Wisconsin School of Medicine and Public Health, to its panel of recognized leaders in the field. The appointments reflect a planned expans

    2/9/26 8:00:00 AM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Carlyle to Host 2026 Shareholder Update

    WASHINGTON and NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Global investment firm Carlyle (NASDAQ:CG) announced today that it will host a Shareholder Update on Thursday, February 26, 2026. The Shareholder Update will include a series of presentations by the company's senior leadership team and will review Carlyle's growth outlook and financial objectives. Presentations will begin at 8:30 a.m. EST, followed by a Q&A session. Presentation materials and a live webcast will be posted on the day of the event and can be accessed on the Events & Presentations section of ir.carlyle.com. For those unable to join the live webcast, a replay will be available on the website following the event. Any

    2/2/26 8:01:00 AM ET
    $CG
    Investment Managers
    Finance

    Acentra Health Appoints Balajee Sethuraman as Executive Vice President and Chief Business Services Officer

    MCLEAN, Va., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions company dedicated to accelerating better health outcomes for government and commercial clients and the populations they serve, today announced the appointment of Balajee Sethuraman as Executive Vice President and Chief Business Services Officer (CBSO), where he will lead the company's business services and delivery operations. This strategic addition to Acentra Health's executive leadership team supports its ongoing efforts to streamline and strengthen enterprise-wide delivery through a unified operating model. "Balajee is a transformative leader with exceptional experience scaling global team

    1/27/26 9:33:00 AM ET
    $CG
    Investment Managers
    Finance

    $ADN
    $ALAR
    $ALIM
    $AUVI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

    SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)

    12/17/24 4:11:23 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    Amendment: SEC Form SC 13D/A filed by Pioneer Municipal High Income Advantage Fund Inc.

    SC 13D/A - PIONEER MUNICIPAL HIGH INCOME ADVANTAGE FUND, INC. (0001258943) (Subject)

    12/13/24 4:29:08 PM ET
    $MAV
    Finance Companies
    Finance

    $ADN
    $ALAR
    $ALIM
    $AUVI
    Financials

    Live finance-specific insights

    View All

    Carlyle Secured Lending, Inc. Schedules Earnings Release and Quarterly Earnings Call to Discuss its Financial Results for the Fourth Quarter and Full Year Ended December 31, 2025

    NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Carlyle Secured Lending, Inc. ("Carlyle Secured Lending") (NASDAQ:CGBD) will host a conference call at 11:00 a.m. (Eastern Time) on Wednesday, February 25, 2026 to announce its financial results for the fourth quarter and full year ended December 31, 2025. The Company will report its quarterly financial results on Tuesday, February 24, 2026. The conference call will be available via public webcast via a link on Carlyle Secured Lending's website at carlylesecuredlending.com and will also be available on the website soon after the call's completion. About Carlyle Secured Lending, Inc.     Carlyle Secured Lending, Inc. is a publicly traded (NASDA

    1/27/26 4:05:00 PM ET
    $CG
    $CGBD
    Investment Managers
    Finance
    Finance: Consumer Services

    FSI ANNOUNCES FOURTH QUARTER AND FULL YEAR 2025 REVENUE

    TABER, ALBERTA, Jan. 23, 2026 (GLOBE NEWSWIRE) -- FLEXIBLE SOLUTIONS INTERNATIONAL, INC. (NYSE-AMERICAN: FSI), is the developer and manufacturer of biodegradable polymers for oil extraction, detergent ingredients and water treatment as well as crop nutrient availability chemistry. Flexible Solutions also manufactures biodegradable and environmentally safe water and energy conservation technologies. In addition, FSI is increasing its presense in the food and nutrition supplement manufacturing markets. Today the Company announces fourth quarter (Q4) and full year, 2025 revenue. Sales were higher in Q4, 2025 compared to Q4, 2024. Flexible Solutions' top line revenue increased from $8.84milli

    1/23/26 9:00:00 AM ET
    $FSI
    Major Chemicals
    Industrials

    Carlyle Credit Income Fund Schedules First Quarter 2026 Financial Results and Investor Conference Call

    NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Carlyle Credit Income Fund ("we," "us," "our," "CCIF" or the "Fund") (NYSE:CCIF) announced today that it will release financial results after market close on Wednesday, February 25, 2026, for its first quarter of 2026. CCIF will host a conference call at 10:00 a.m. EST on Thursday, February 26, 2026, to discuss the results. The conference call will be available via public webcast via a link on Carlyle Credit Income Fund's website at www.carlylecreditincomefund.com and a replay will also be available on the website soon after the call's completion. About Carlyle Credit Income Fund Carlyle Credit Income Fund (NYSE:CCIF) is an externally managed

    1/22/26 4:10:00 PM ET
    $CCIF
    $CG
    Finance/Investors Services
    Finance
    Investment Managers